Alkermes Plc Stock News

DUBLIN , Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd Annual J.P. Morgan Healthcare Conference.

DUBLIN , Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 7th Annual Evercore ISI HealthCONx Conference Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m.

Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy and hypersomnia, represents a transformative opportunity in a $7.3 billion market by 2032. With $908.9 million in liquidity and a positive cash flow of $73.3 million in Q3, Alkermes can effectivel...

The top five biotech stocks today have several commonalities. Among them are strong ratings.

DUBLIN , Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare Conference Date/Time: Monday, Nov. 18, 2024 at 8:35 a.m.

– 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy – – Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization and Treatment Patterns in Patients With Schizophrenia or Bipolar I Disorder Following Initiation of LYBALVI®(olanzapine and samidorphan) – DUBLIN , Nov. 7, 2024 /PRNewswire/ -- Alkermes plc  (Nasdaq: ALKS) to...

Alkermes plc (NASDAQ:ALKS ) Q3 2024 Earnings Conference Call October 24, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Richard Pops - CEO Todd Nichols - Chief Commercial Officer Blair Jackson - Chief Operating Officer. Conference Call Participants Joseph Thome - TD Cowen Umer Raffat - Evercore Paul Matteis - Stifel Charles...

— Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported fi...